| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
bosentan is a weak inducer of CYP2C9 and CYP3A.
|Weak inducers||aprepitant [a] |
|aprepitant  |
ginko biloba 
- Weak inducers: < 2-fold decrease in AUC or < 50% increase in clearance of in vivo CYP probe.
Footnotes and References
|a.||assessment based on product information accessed via the Therapeutic Goods Administration of Australia Product and Consumer Medicines Information website ( https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=&r=https://www.ebs.tga.gov.au/ ).|
|b.||reported at Clinical Trials.gov ( http://clinicaltrials.gov/ct2/show/study/NCT00785486?sect=X701&view=results ).|
|1.||Lai ML, Lin TS, Huang JD. Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. European Journal of Clinical Pharmacology 1992; 43: 201-03.[PubMed]|
|2.||Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJJ, Klein CE, Rublein JC, Kashuba ADM. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes 2006; 42: 52-60.[PubMed]|
|3.||Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blu RA. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. Journal of Clinical Pharmacology 2004; 44: 215-23.[PubMed]|
|4.||Dingemanse J, Schaarschmidt D, van Giersbergen PLM. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clinical Pharmacokinetics 2003; 42: 293-301.[PubMed]|
|5.||Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998; 83: 135-38.[PubMed]|
|6.||Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolarn and fexofenadine pharmacokinetics in healthy subjects. Current Medical Research and Opinion 2008; 24: 591-99.[PubMed]|
|7.||Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam pharmacokinetics. British Journal of Clinical Pharmacology 1987; 23: 759-63.[PubMed]|
|8.||Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British Journal of Clinical Pharmacology 1995; 40: 270-72.[PubMed]|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.